Feb 22, 2022
A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.
Feb 11, 2022
A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer vaccine) booster.